DK1737962T3 - GAS1-universel leder - Google Patents

GAS1-universel leder

Info

Publication number
DK1737962T3
DK1737962T3 DK05729650.1T DK05729650T DK1737962T3 DK 1737962 T3 DK1737962 T3 DK 1737962T3 DK 05729650 T DK05729650 T DK 05729650T DK 1737962 T3 DK1737962 T3 DK 1737962T3
Authority
DK
Denmark
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
DK05729650.1T
Other languages
English (en)
Inventor
Wildt Rudolph M T De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Application granted granted Critical
Publication of DK1737962T3 publication Critical patent/DK1737962T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK05729650.1T 2004-03-24 2005-03-24 GAS1-universel leder DK1737962T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
DK1737962T3 true DK1737962T3 (da) 2010-12-13

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05729650.1T DK1737962T3 (da) 2004-03-24 2005-03-24 GAS1-universel leder

Country Status (11)

Country Link
US (1) US7846721B2 (da)
EP (2) EP2172553A1 (da)
AT (1) ATE479760T1 (da)
CY (1) CY1111063T1 (da)
DE (1) DE602005023291D1 (da)
DK (1) DK1737962T3 (da)
ES (1) ES2351509T3 (da)
PL (1) PL1737962T3 (da)
PT (1) PT1737962E (da)
SI (1) SI1737962T1 (da)
WO (1) WO2005093074A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2010063818A2 (en) 2008-12-05 2010-06-10 Glaxo Group Limited Methods for selecting protease resistant polypeptides
ES2655071T3 (es) 2009-02-19 2018-02-16 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
EA022925B1 (ru) 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
MX2011008752A (es) 2009-02-19 2011-09-06 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas.
WO2011006914A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
EP2454285A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
KR20120063475A (ko) 2009-07-29 2012-06-15 글락소 그룹 리미티드 항-tgf-베타 수용체 타입 ⅱ 단일 도메인 항체
JP2013516967A (ja) 2010-01-14 2013-05-16 グラクソ グループ リミテッド 肝臓標的化ドメイン抗体
JP2013528362A (ja) 2010-04-21 2013-07-11 グラクソ グループ リミテッド 結合ドメイン
EA201291009A1 (ru) 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
WO2012021749A1 (en) * 2010-08-11 2012-02-16 Celula, Inc. Genotyping dna
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
PE20140982A1 (es) 2011-01-06 2014-08-22 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
PL2870247T3 (pl) * 2012-07-05 2019-10-31 Hoffmann La Roche Układ ekspresji i wydzielania
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
EP2172553A1 (en) 2010-04-07
ATE479760T1 (de) 2010-09-15
WO2005093074A1 (en) 2005-10-06
ES2351509T3 (es) 2011-02-07
EP1737962B1 (en) 2010-09-01
CY1111063T1 (el) 2015-06-11
US20070026462A1 (en) 2007-02-01
DE602005023291D1 (de) 2010-10-14
SI1737962T1 (sl) 2011-01-31
PL1737962T3 (pl) 2011-02-28
EP1737962A1 (en) 2007-01-03
US7846721B2 (en) 2010-12-07
PT1737962E (pt) 2010-12-03

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
ATE402267T1 (de) Verfahren zur herstellung von monoklonalen antikörpern
ATE517124T1 (de) Verfahren zum nachweis von probnp mit einem monoklonalen antikörper, der die amino saüre 42- 46 bindet
DE60333793D1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
DK1831362T3 (da) Syreaktive svampeproteaser
ATE503009T1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
JP2014061000A5 (da)
BRPI0716997B8 (pt) proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE477277T1 (de) Weniger immunogene bindungsmoleküle
ATE424458T1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
ATE443870T1 (de) Verfahren zur charakterisierung einer polyklonalen zellinie
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
WO2008057637A3 (en) Methods of increasing secretion of polypeptides having biological activity
ATE501266T1 (de) Verfahren zur fermentativen herstellung von antikörpern
DE60026733D1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
ATE444370T1 (de) Expressionsvektor zur sekretion eines antikörperfragments unter verwendung einer e.coli-signalsequenz sowie verfahren zur massenproduktion des antikörperfragments
ATE525642T1 (de) Sensoranordnung und herstellungsverfahren für einen durch kapillareffekt gefüllten diagnose- sensor
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
WO2007019064A3 (en) ANTI-TNFα ANTIBODIES AND METHODS OF USE
CN201069430Y (zh) 表面矿物料粘附性测试仪